ID   CSK_HUMAN               Reviewed;         450 AA.
AC   P41240; Q2M3N2; Q6FGZ6;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1995, sequence version 1.
DT   10-MAY-2017, entry version 196.
DE   RecName: Full=Tyrosine-protein kinase CSK;
DE            EC=2.7.10.2 {ECO:0000269|PubMed:1639064, ECO:0000269|PubMed:7683130, ECO:0000269|PubMed:9281320};
DE   AltName: Full=C-Src kinase;
DE   AltName: Full=Protein-tyrosine kinase CYL;
GN   Name=CSK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PHOSPHORYLATION AT TYR-416.
RX   PubMed=1945408;
RA   Partanen J., Armstrong E., Bergman M., Maekelae T.P., Hirvonen H.,
RA   Huebner K., Alitalo K.;
RT   "CYL encodes a putative cytoplasmic tyrosine kinase lacking the
RT   conserved tyrosine autophosphorylation site (Y416src).";
RL   Oncogene 6:2013-2018(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   PubMed=1720539; DOI=10.1073/pnas.88.23.10411;
RA   Braeuninger A., Holtrich U., Strebhardt K., Ruebsamen-Waigmann H.;
RT   "Two additional protein-tyrosine kinases expressed in human lung:
RT   fourth member of the fibroblast growth factor receptor family and an
RT   intracellular protein-tyrosine kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:10411-10415(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RX   PubMed=1371489; DOI=10.1016/0378-1119(92)90649-A;
RA   Brauninger A., Holtrich U., Strebhardt K., Rubsamen-Waigmann H.;
RT   "Isolation and characterization of a human gene that encodes a new
RT   subclass of protein tyrosine kinases.";
RL   Gene 110:205-211(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7683131;
RA   Braeuninger A., Karn T., Strebhardt K., Ruebsamen-Waigmann H.;
RT   "Characterization of the human CSK locus.";
RL   Oncogene 8:1365-1369(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ASP-287; GLN-398 AND
RP   ARG-442.
RG   NIEHS SNPs program;
RL   Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF LCK, CATALYTIC ACTIVITY, AND COFACTOR.
RX   PubMed=1639064;
RA   Bergman M., Mustelin T., Oetken C., Partanen J., Flint N.A.,
RA   Amrein K.E., Autero M., Burn P., Alitalo K.;
RT   "The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and
RT   down regulates its catalytic activity.";
RL   EMBO J. 11:2919-2924(1992).
RN   [9]
RP   AUTOPHOSPHORYLATION, AND CATALYTIC ACTIVITY.
RX   PubMed=7683130;
RA   Bougeret C., Rothhut B., Jullien P., Fischer S., Benarous R.;
RT   "Recombinant Csk expressed in Escherichia coli is autophosphorylated
RT   on tyrosine residue(s).";
RL   Oncogene 8:1241-1247(1993).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF YES1, CATALYTIC ACTIVITY, AND COFACTOR.
RX   PubMed=9281320; DOI=10.1006/abbi.1997.0236;
RA   Sun G., Budde R.J.;
RT   "Expression, purification, and initial characterization of human Yes
RT   protein tyrosine kinase from a bacterial expression system.";
RL   Arch. Biochem. Biophys. 345:135-142(1997).
RN   [11]
RP   PHOSPHORYLATION AT TYR-184 AND TYR-304, AND MUTAGENESIS OF TYR-184 AND
RP   TYR-304.
RX   PubMed=9148770; DOI=10.1042/bj3220927;
RA   Joukov V., Vihinen M., Vainikka S., Sowadski J.M., Alitalo K.,
RA   Bergman M.;
RT   "Identification of csk tyrosine phosphorylation sites and a tyrosine
RT   residue important for kinase domain structure.";
RL   Biochem. J. 322:927-935(1997).
RN   [12]
RP   INTERACTION WITH TGFB1I1.
RX   PubMed=10838081; DOI=10.1016/S0014-5793(00)01597-0;
RA   Ishino M., Aoto H., Sasaski H., Suzuki R., Sasaki T.;
RT   "Phosphorylation of Hic-5 at tyrosine 60 by CAKbeta and Fyn.";
RL   FEBS Lett. 474:179-183(2000).
RN   [13]
RP   INTERACTION WITH PAG1.
RX   PubMed=10790433; DOI=10.1084/jem.191.9.1591;
RA   Brdicka T., Pavlistova D., Bruyns E., Leo A., Korinek V.,
RA   Angelisova P., Scherer J., Shevchenko A., Shevchenko A., Hilgert I.,
RA   Cerny J., Drbal K., Kuramitsu Y., Horejsi V., Schraven B.;
RT   "Phosphoprotein associated with glycosphingolipid-enriched
RT   microdomains (PAG), a novel ubiquitously expressed transmembrane
RT   adaptor protein, binds the protein tyrosine kinase csk and is involved
RT   in regulation of T cell activation.";
RL   J. Exp. Med. 191:1591-1604(2000).
RN   [14]
RP   INTERACTION WITH SIT1.
RX   PubMed=11433379;
RX   DOI=10.1002/1521-4141(200106)31:6<1825::AID-IMMU1825>3.0.CO;2-V;
RA   Pfrepper K.-I., Marie-Cardine A., Simeoni L., Kuramitsu Y., Leo A.,
RA   Spicka J., Hilgert I., Scherer J., Schraven B.;
RT   "Structural and functional dissection of the cytoplasmic domain of the
RT   transmembrane adaptor protein SIT (SHP2-interacting transmembrane
RT   adaptor protein).";
RL   Eur. J. Immunol. 31:1825-1836(2001).
RN   [15]
RP   PHOSPHORYLATION AT SER-364 BY PKA, AND MUTAGENESIS OF SER-364.
RX   PubMed=11181701; DOI=10.1084/jem.193.4.497;
RA   Vang T., Torgersen K.M., Sundvold V., Saxena M., Levy F.O.,
RA   Skalhegg B.S., Hansson V., Mustelin T., Tasken K.;
RT   "Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent
RT   protein kinase inhibits signaling through the T cell receptor.";
RL   J. Exp. Med. 193:497-507(2001).
RN   [16]
RP   INTERACTION WITH LIME1.
RX   PubMed=14610046; DOI=10.1084/jem.20031484;
RA   Brdickova N., Brdicka T., Angelisova P., Horvath O., Spicka J.,
RA   Hilgert I., Paces J., Simeoni L., Kliche S., Merten C., Schraven B.,
RA   Horejsi V.;
RT   "LIME: a new membrane raft-associated adaptor protein involved in CD4
RT   and CD8 coreceptor signaling.";
RL   J. Exp. Med. 198:1453-1462(2003).
RN   [17]
RP   INTERACTION WITH PTPN22.
RX   PubMed=15208781; DOI=10.1086/422827;
RA   Begovich A.B., Carlton V.E., Honigberg L.A., Schrodi S.J.,
RA   Chokkalingam A.P., Alexander H.C., Ardlie K.G., Huang Q., Smith A.M.,
RA   Spoerke J.M., Conn M.T., Chang M., Chang S.Y., Saiki R.K.,
RA   Catanese J.J., Leong D.U., Garcia V.E., McAllister L.B., Jeffery D.A.,
RA   Lee A.T., Batliwalla F., Remmers E., Criswell L.A., Seldin M.F.,
RA   Kastner D.L., Amos C.I., Sninsky J.J., Gregersen P.K.;
RT   "A missense single-nucleotide polymorphism in a gene encoding a
RT   protein tyrosine phosphatase (PTPN22) is associated with rheumatoid
RT   arthritis.";
RL   Am. J. Hum. Genet. 75:330-337(2004).
RN   [18]
RP   REVIEW.
RX   PubMed=16243715; DOI=10.1080/08977190500178877;
RA   Chong Y.P., Mulhern T.D., Cheng H.C.;
RT   "C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK)--
RT   endogenous negative regulators of Src-family protein kinases.";
RL   Growth Factors 23:233-244(2005).
RN   [19]
RP   INTERACTION WITH SRCIN1.
RX   PubMed=17525734; DOI=10.1038/sj.emboj.7601724;
RA   Di Stefano P., Damiano L., Cabodi S., Aramu S., Tordella L.,
RA   Praduroux A., Piva R., Cavallo F., Forni G., Silengo L., Tarone G.,
RA   Turco E., Defilippi P.;
RT   "p140Cap protein suppresses tumour cell properties, regulating Csk and
RT   Src kinase activity.";
RL   EMBO J. 26:2843-2855(2007).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [21]
RP   HOMODIMERIZATION.
RX   PubMed=19888460; DOI=10.1371/journal.pone.0007683;
RA   Levinson N.M., Visperas P.R., Kuriyan J.;
RT   "The tyrosine kinase Csk dimerizes through Its SH3 domain.";
RL   PLoS ONE 4:E7683-E7683(2009).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [23]
RP   INTERACTION WITH RHOH.
RX   PubMed=20851766; DOI=10.1016/j.cellsig.2010.09.009;
RA   Wang H., Zeng X., Fan Z., Lim B.;
RT   "RhoH modulates pre-TCR and TCR signalling by regulating LCK.";
RL   Cell. Signal. 23:249-258(2011).
RN   [24]
RP   INTERACTION WITH SCIMP.
RX   PubMed=21930792; DOI=10.1128/MCB.05817-11;
RA   Draber P., Vonkova I., Stepanek O., Hrdinka M., Kucova M.,
RA   Skopcova T., Otahal P., Angelisova P., Horejsi V., Yeung M., Weiss A.,
RA   Brdicka T.;
RT   "SCIMP, a transmembrane adapter protein involved in major
RT   histocompatibility complex class II signaling.";
RL   Mol. Cell. Biol. 31:4550-4562(2011).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-71.
RX   PubMed=7511113; DOI=10.1016/0014-5793(94)80244-0;
RA   Borchert T.V., Mathieu M., Zeelen J.P., Courtneidge S.A.,
RA   Wierenga R.K.;
RT   "The crystal structure of human CskSH3: structural diversity near the
RT   RT-Src and n-Src loop.";
RL   FEBS Lett. 341:79-85(1994).
RN   [26]
RP   VARIANT [LARGE SCALE ANALYSIS] LEU-45.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase that plays an
CC       important role in the regulation of cell growth, differentiation,
CC       migration and immune response. Phosphorylates tyrosine residues
CC       located in the C-terminal tails of Src-family kinases (SFKs)
CC       including LCK, SRC, HCK, FYN, LYN or YES1. Upon tail
CC       phosphorylation, Src-family members engage in intramolecular
CC       interactions between the phosphotyrosine tail and the SH2 domain
CC       that result in an inactive conformation. To inhibit SFKs, CSK is
CC       recruited to the plasma membrane via binding to transmembrane
CC       proteins or adapter proteins located near the plasma membrane.
CC       Suppresses signaling by various surface receptors, including T-
CC       cell receptor (TCR) and B-cell receptor (BCR) by phosphorylating
CC       and maintaining inactive several positive effectors such as FYN or
CC       LCK. {ECO:0000269|PubMed:1639064, ECO:0000269|PubMed:9281320}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000269|PubMed:1639064,
CC       ECO:0000269|PubMed:7683130, ECO:0000269|PubMed:9281320}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:9281320};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:1639064};
CC   -!- SUBUNIT: Homodimer (via SH3-domain) (PubMed:19888460). Interacts
CC       with PTPN22 (PubMed:15208781). Interacts with phosphorylated SIT1,
CC       PAG1, LIME1 and TGFB1I1; these interactions serve to recruit CSK
CC       to the membrane where it can phosphorylate and inhibit Src-family
CC       kinases (PubMed:11433379, PubMed:10790433, PubMed:14610046,
CC       PubMed:10838081). Interacts with SRCIN1 (PubMed:17525734).
CC       Interacts with RHOH (PubMed:20851766). Interacts (via SH2 domain)
CC       with SCIMP (PubMed:21930792). {ECO:0000269|PubMed:10790433,
CC       ECO:0000269|PubMed:10838081, ECO:0000269|PubMed:11433379,
CC       ECO:0000269|PubMed:14610046, ECO:0000269|PubMed:15208781,
CC       ECO:0000269|PubMed:17525734, ECO:0000269|PubMed:20851766,
CC       ECO:0000269|PubMed:21930792}.
CC   -!- INTERACTION:
CC       Self; NbExp=7; IntAct=EBI-1380630, EBI-1380630;
CC       P08069:IGF1R; NbExp=5; IntAct=EBI-1380630, EBI-475981;
CC       Q9NWQ8:PAG1; NbExp=3; IntAct=EBI-1380630, EBI-2828115;
CC       P08575:PTPRC; NbExp=3; IntAct=EBI-1380630, EBI-1341;
CC       P49023:PXN; NbExp=2; IntAct=EBI-1380630, EBI-702209;
CC       P00523:SRC (xeno); NbExp=6; IntAct=EBI-1380630, EBI-848039;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Cell membrane
CC       {ECO:0000250}. Note=Mainly cytoplasmic, also present in lipid
CC       rafts. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in lung and macrophages.
CC       {ECO:0000269|PubMed:1371489}.
CC   -!- DOMAIN: The architecture of this protein is similar to that of
CC       Src-family kinases (SFKs) with one N-terminal SH3 domain, one SH2
CC       domain, and a C-terminal kinase domain.
CC   -!- PTM: Phosphorylated at Ser-364 by PKA, leading to increased
CC       activity. Autophosphorylated. {ECO:0000269|PubMed:11181701,
CC       ECO:0000269|PubMed:9148770}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSK subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/csk/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X60114; CAA42713.1; -; mRNA.
DR   EMBL; X59932; CAA42556.1; -; mRNA.
DR   EMBL; X74765; CAB58562.1; -; Genomic_DNA.
DR   EMBL; CR541960; CAG46758.1; -; mRNA.
DR   EMBL; DQ075211; AAY57329.1; -; Genomic_DNA.
DR   EMBL; BC104847; AAI04848.1; -; mRNA.
DR   EMBL; BC104875; AAI04876.1; -; mRNA.
DR   EMBL; BC106073; AAI06074.1; -; mRNA.
DR   CCDS; CCDS10269.1; -.
DR   PIR; JH0559; JH0559.
DR   RefSeq; NP_001120662.1; NM_001127190.1.
DR   RefSeq; NP_004374.1; NM_004383.2.
DR   RefSeq; XP_005254222.1; XM_005254165.4.
DR   RefSeq; XP_016877414.1; XM_017021925.1.
DR   UniGene; Hs.77793; -.
DR   PDB; 1BYG; X-ray; 2.40 A; A=173-450.
DR   PDB; 1CSK; X-ray; 2.50 A; A/B/C/D=1-71.
DR   PDB; 3D7T; X-ray; 2.90 A; A=188-450.
DR   PDB; 3D7U; X-ray; 4.11 A; A/C=188-450.
DR   PDB; 3EAC; X-ray; 1.37 A; A=73-178.
DR   PDB; 3EAZ; X-ray; 1.31 A; A=73-178.
DR   PDBsum; 1BYG; -.
DR   PDBsum; 1CSK; -.
DR   PDBsum; 3D7T; -.
DR   PDBsum; 3D7U; -.
DR   PDBsum; 3EAC; -.
DR   PDBsum; 3EAZ; -.
DR   ProteinModelPortal; P41240; -.
DR   SMR; P41240; -.
DR   BioGrid; 107832; 54.
DR   IntAct; P41240; 38.
DR   MINT; MINT-85878; -.
DR   STRING; 9606.ENSP00000220003; -.
DR   BindingDB; P41240; -.
DR   ChEMBL; CHEMBL2634; -.
DR   DrugBank; DB02010; Staurosporine.
DR   DrugBank; DB05075; TG100801.
DR   GuidetoPHARMACOLOGY; 1994; -.
DR   iPTMnet; P41240; -.
DR   PhosphoSitePlus; P41240; -.
DR   BioMuta; CSK; -.
DR   DMDM; 729887; -.
DR   OGP; P41240; -.
DR   EPD; P41240; -.
DR   MaxQB; P41240; -.
DR   PaxDb; P41240; -.
DR   PeptideAtlas; P41240; -.
DR   PRIDE; P41240; -.
DR   DNASU; 1445; -.
DR   Ensembl; ENST00000220003; ENSP00000220003; ENSG00000103653.
DR   Ensembl; ENST00000439220; ENSP00000414764; ENSG00000103653.
DR   Ensembl; ENST00000567571; ENSP00000454906; ENSG00000103653.
DR   GeneID; 1445; -.
DR   KEGG; hsa:1445; -.
DR   UCSC; uc002ays.3; human.
DR   CTD; 1445; -.
DR   DisGeNET; 1445; -.
DR   GeneCards; CSK; -.
DR   HGNC; HGNC:2444; CSK.
DR   HPA; CAB011203; -.
DR   HPA; HPA026488; -.
DR   HPA; HPA028425; -.
DR   MIM; 124095; gene.
DR   neXtProt; NX_P41240; -.
DR   OpenTargets; ENSG00000103653; -.
DR   PharmGKB; PA26946; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000119011; -.
DR   HOGENOM; HOG000233858; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; P41240; -.
DR   KO; K05728; -.
DR   OMA; TRDPNWY; -.
DR   OrthoDB; EOG091G05PB; -.
DR   PhylomeDB; P41240; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-180292; GAB1 signalosome.
DR   Reactome; R-HSA-202427; Phosphorylation of CD3 and TCR zeta chains.
DR   Reactome; R-HSA-354192; Integrin alphaIIb beta3 signaling.
DR   Reactome; R-HSA-389948; PD-1 signaling.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802949; Signaling by RAS mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   SignaLink; P41240; -.
DR   SIGNOR; P41240; -.
DR   EvolutionaryTrace; P41240; -.
DR   GeneWiki; C-src_tyrosine_kinase; -.
DR   GenomeRNAi; 1445; -.
DR   PRO; PR:P41240; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000103653; -.
DR   CleanEx; HS_CSK; -.
DR   ExpressionAtlas; P41240; baseline and differential.
DR   Genevisible; P41240; HS.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; TAS:HGNC.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IPI:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0016301; F:kinase activity; TAS:Reactome.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0070064; F:proline-rich region binding; IEA:Ensembl.
DR   GO; GO:0008022; F:protein C-terminus binding; TAS:ProtInc.
DR   GO; GO:0034236; F:protein kinase A catalytic subunit binding; IPI:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IEA:Ensembl.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0005102; F:receptor binding; IBA:GO_Central.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0034332; P:adherens junction organization; IBA:GO_Central.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0071375; P:cellular response to peptide hormone stimulus; IEA:Ensembl.
DR   GO; GO:0007417; P:central nervous system development; IBA:GO_Central.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0045779; P:negative regulation of bone resorption; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0042997; P:negative regulation of Golgi to plasma membrane protein transport; IDA:UniProtKB.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; IEA:Ensembl.
DR   GO; GO:0033673; P:negative regulation of kinase activity; IEA:Ensembl.
DR   GO; GO:0010989; P:negative regulation of low-density lipoprotein particle clearance; IEA:Ensembl.
DR   GO; GO:0050765; P:negative regulation of phagocytosis; IEA:Ensembl.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0001817; P:regulation of cytokine production; IBA:GO_Central.
DR   GO; GO:0060368; P:regulation of Fc receptor mediated stimulatory signaling pathway; IBA:GO_Central.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Adaptive immunity; ATP-binding;
KW   Cell membrane; Complete proteome; Cytoplasm; Immunity; Kinase;
KW   Magnesium; Manganese; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome; SH2 domain;
KW   SH3 domain; Transferase; Tyrosine-protein kinase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2    450       Tyrosine-protein kinase CSK.
FT                                /FTId=PRO_0000088070.
FT   DOMAIN        9     70       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN       82    171       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      195    449       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     201    209       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        9     70       Interaction with PTPN22.
FT                                {ECO:0000250|UniProtKB:P41241}.
FT   ACT_SITE    314    314       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     222    222       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES     184    184       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:9148770}.
FT   MOD_RES     304    304       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:9148770}.
FT   MOD_RES     364    364       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:11181701}.
FT   MOD_RES     416    416       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:1945408}.
FT   VARIANT      45     45       P -> L. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041678.
FT   VARIANT     287    287       G -> D (in dbSNP:rs34866753).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_025203.
FT   VARIANT     398    398       R -> Q (in dbSNP:rs34616395).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_025204.
FT   VARIANT     442    442       H -> R (in dbSNP:rs35556162).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_025205.
FT   MUTAGEN     184    184       Y->F: Abolishes phosphorylation.
FT                                {ECO:0000269|PubMed:9148770}.
FT   MUTAGEN     304    304       Y->F: Decreases activity by two-thirds
FT                                and alters conformation.
FT                                {ECO:0000269|PubMed:9148770}.
FT   MUTAGEN     364    364       S->A: Strong decrease of phosphorylation
FT                                by PRKACA (catalytic subunit of PKA).
FT                                {ECO:0000269|PubMed:11181701}.
FT   STRAND       12     18       {ECO:0000244|PDB:1CSK}.
FT   STRAND       35     41       {ECO:0000244|PDB:1CSK}.
FT   STRAND       47     51       {ECO:0000244|PDB:1CSK}.
FT   STRAND       57     61       {ECO:0000244|PDB:1CSK}.
FT   STRAND       64     66       {ECO:0000244|PDB:1CSK}.
FT   HELIX        77     79       {ECO:0000244|PDB:3EAZ}.
FT   STRAND       83     86       {ECO:0000244|PDB:3EAC}.
FT   HELIX        89     95       {ECO:0000244|PDB:3EAZ}.
FT   STRAND      103    108       {ECO:0000244|PDB:3EAZ}.
FT   STRAND      116    122       {ECO:0000244|PDB:3EAZ}.
FT   STRAND      125    130       {ECO:0000244|PDB:3EAZ}.
FT   STRAND      132    134       {ECO:0000244|PDB:3EAZ}.
FT   STRAND      137    144       {ECO:0000244|PDB:3EAZ}.
FT   STRAND      146    148       {ECO:0000244|PDB:3EAZ}.
FT   HELIX       149    158       {ECO:0000244|PDB:3EAZ}.
FT   STRAND      163    165       {ECO:0000244|PDB:3EAZ}.
FT   HELIX       192    194       {ECO:0000244|PDB:1BYG}.
FT   STRAND      195    203       {ECO:0000244|PDB:1BYG}.
FT   STRAND      208    214       {ECO:0000244|PDB:1BYG}.
FT   STRAND      217    223       {ECO:0000244|PDB:1BYG}.
FT   HELIX       231    235       {ECO:0000244|PDB:1BYG}.
FT   HELIX       237    240       {ECO:0000244|PDB:1BYG}.
FT   STRAND      251    255       {ECO:0000244|PDB:1BYG}.
FT   STRAND      263    266       {ECO:0000244|PDB:1BYG}.
FT   HELIX       274    285       {ECO:0000244|PDB:1BYG}.
FT   HELIX       288    307       {ECO:0000244|PDB:1BYG}.
FT   HELIX       317    319       {ECO:0000244|PDB:1BYG}.
FT   STRAND      320    322       {ECO:0000244|PDB:1BYG}.
FT   STRAND      328    330       {ECO:0000244|PDB:1BYG}.
FT   TURN        350    352       {ECO:0000244|PDB:1BYG}.
FT   HELIX       355    360       {ECO:0000244|PDB:1BYG}.
FT   HELIX       365    380       {ECO:0000244|PDB:1BYG}.
FT   HELIX       392    394       {ECO:0000244|PDB:1BYG}.
FT   HELIX       395    399       {ECO:0000244|PDB:1BYG}.
FT   TURN        400    402       {ECO:0000244|PDB:1BYG}.
FT   HELIX       413    422       {ECO:0000244|PDB:1BYG}.
FT   HELIX       427    429       {ECO:0000244|PDB:1BYG}.
FT   HELIX       433    446       {ECO:0000244|PDB:1BYG}.
SQ   SEQUENCE   450 AA;  50704 MW;  431023A88C54E00C CRC64;
     MSAIQAAWPS GTECIAKYNF HGTAEQDLPF CKGDVLTIVA VTKDPNWYKA KNKVGREGII
     PANYVQKREG VKAGTKLSLM PWFHGKITRE QAERLLYPPE TGLFLVREST NYPGDYTLCV
     SCDGKVEHYR IMYHASKLSI DEEVYFENLM QLVEHYTSDA DGLCTRLIKP KVMEGTVAAQ
     DEFYRSGWAL NMKELKLLQT IGKGEFGDVM LGDYRGNKVA VKCIKNDATA QAFLAEASVM
     TQLRHSNLVQ LLGVIVEEKG GLYIVTEYMA KGSLVDYLRS RGRSVLGGDC LLKFSLDVCE
     AMEYLEGNNF VHRDLAARNV LVSEDNVAKV SDFGLTKEAS STQDTGKLPV KWTAPEALRE
     KKFSTKSDVW SFGILLWEIY SFGRVPYPRI PLKDVVPRVE KGYKMDAPDG CPPAVYEVMK
     NCWHLDAAMR PSFLQLREQL EHIKTHELHL
//
